314 related articles for article (PubMed ID: 30003192)
1. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.
Hazama S; Tamada K; Yamaguchi Y; Kawakami Y; Nagano H
Ann Gastroenterol Surg; 2018 Jul; 2(4):289-303. PubMed ID: 30003192
[TBL] [Abstract][Full Text] [Related]
2. Current status of vaccine immunotherapy for gastrointestinal cancers.
Suzuki N; Shindo Y; Nakajima M; Tsunedomi R; Nagano H
Surg Today; 2023 Dec; ():. PubMed ID: 38043066
[TBL] [Abstract][Full Text] [Related]
3. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
4. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
5. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
6. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
7. Current Immunotherapeutic Approaches for Malignant Gliomas.
Han MH; Kim CH
Brain Tumor Res Treat; 2022 Jan; 10(1):1-11. PubMed ID: 35118842
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
10. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
[TBL] [Abstract][Full Text] [Related]
12. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Kim BJ; Jang HJ; Kim HS; Kim JH
J Cancer; 2017; 8(8):1460-1465. PubMed ID: 28638461
[TBL] [Abstract][Full Text] [Related]
15. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
16. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies.
Raghani NR; Chorawala MR; Mahadik M; Patel RB; Prajapati BG; Parekh PS
Med Oncol; 2024 Jan; 41(2):51. PubMed ID: 38195781
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Long J; Lin J; Wang A; Wu L; Zheng Y; Yang X; Wan X; Xu H; Chen S; Zhao H
J Hematol Oncol; 2017 Aug; 10(1):146. PubMed ID: 28774337
[TBL] [Abstract][Full Text] [Related]
18. Targeting lactate metabolism for cancer immunotherapy - a matter of precision.
Heuser C; Renner K; Kreutz M; Gattinoni L
Semin Cancer Biol; 2023 Jan; 88():32-45. PubMed ID: 36496155
[TBL] [Abstract][Full Text] [Related]
19. Emerging immunotherapy for HCC: A guide for hepatologists.
Foerster F; Gairing SJ; Ilyas SI; Galle PR
Hepatology; 2022 Jun; 75(6):1604-1626. PubMed ID: 35253934
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
